Figure 1.
Design of the animal intervention studies. TNBS (black ellipse) was administered intrarectally on day (D) 0 and mice were killed 2 or 5 d later. The rexinoid (LG101305), the PPARγ agonists, such as rosiglitazone and troglitazone, or the combination of a rexinoid and a PPARγ agonist were administered at the indicated doses 2 d before the induction of colitis (preventive mode). The therapeutic effects were evaluated in mice receiving the same dose of rosiglitazone just after TNBS administration (therapeutic mode). Treatment with PPARγ and/or RXR agonists was evaluated at day 2 or 5 by scoring for mortality, determination of macroscopic and histologic inflammation scores, and measurements of inflammatory parameters (MPO levels, TNF-α and IL-1β mRNA, NF-κB pathway, and MAPK activity).